-Dividend pay-out increases
-US growth to continue
-Stock too expensive for many
By Eva Brocklehurst
James Hardie ((JHX)) has gone from strength to strength recently. The third quarter results bettered broker expectations, with higher prices and lower costs offsetting a shortfall in US fibre cement volumes.
When FNArena last looked at James Hardie, ahead of the first quarter, the observation was made by Goldman Sachs that the company had not responded very well to the first signs of improvement in US housing starts. The reason given was that the initial recovery was centred on low value multi-residential developments and, with an upturn to single dwelling construction and more broad-based recovery, the fortunes of the company would change. Now, it seems the company has started to score on this measure. The third quarter result was not robust but brokers were pleasantly surprised with a US28c special dividend.
To the brokers, this special dividend not only signals a change in strategy to return more capital to shareholders but also that management is very positive about the growth outlook. Deutsche Bank believes, despite the increase to capex intentions for FY15-17, the company can pay a US40c special dividend in FY15 and FY16, as well as continue with its buy-back. Underpinning these expectations is management's raising of net debt forecasts to more than US$500m by FY16.
UBS observes that, during the downturn, volume declines were limited by the company actively growing the renovations market to over 60% of volumes. Now, a 10% growth in housing starts translates to 17% growth in total US volumes for James Hardie. This ability to maximise such leverage makes the stock attractive and may signal renewed success in growing market share, according to UBS.
Having said that, the broker thinks the US recovery may be buffeted by a tapering of the US Federal Reserve's quantitative easing, as well as the weather. In terms of the latter, the upcoming US spring season should help to gauge the strength of the US housing recovery. Nevertheless, the broker thinks the stock is too expensive. The market is seemly pricing in super-normal margins and high market share. UBS expects profits will ultimately be whittled away by competition, or margins will be maintained at the expensive of market share. Either way, a Sell rating stays in place.
James Hardie surprised JP Morgan with the extent of the reduction in unit operating costs. As confidence is building, the market's attention is shifting more to what James Hardie could be worth, in JP Morgan's opinion. If price growth, market share and terminal margins all reach JP Morgan's top assumptions the stock could be worth up to $19.50. Such assumptions are not for the faint hearted, the broker acknowledges, as they require perfect conditions. Hence, JP Morgan's base case price target is $13.80 and the recommendation is Neutral.
Credit Suisse has a slightly different take. The broker senses that management is confident about generating sufficient free cash flow to meet liabilities and fund growth as well a return capital and expects this belief, for now, should overshadow an emerging soft patch in housing activity in the US. The current strength in the US market has led the company to accelerate capacity expansion, having previously announced a 26% increase in US fibre cement capacity at a cost of US$136m. If the business continues on the same trajectory, Credit Suisse thinks the capex budget will be revised higher.
The broker gives credit to the company's operations team and has greater confidence in the company's ability to penetrate the market with its pricing model. Why then downgrade to Neutral from Outperform? The run up in the share price over the past quarter has made the stock expensive and Credit Suisse awaits a more attractive entry point.
James Hardie is one of the most difficult when it comes to formulating an investment outlook, according to CIMB. The US housing market recovery has further to go and the company is growing its share in a growing market. The returns are impressive and shareholders should soon see a greater portion allotted to them. It's all good, but the valuation plagues the broker. CIMB's discounted cash flow valuation of $11.07 is 25% below current price levels. Even on FY16 earnings forecasts the stock trades at a price/earnings ratio of 19 times, adjusting for asbestos. Hence, CIMB's fundamental valuation is retained and so is a Reduce rating.
Macquarie liked the strong results but didn't like the increase in new asbestos claims. Management is not sure whether this is the start of a trend but the broker think the situation needs to be monitored closely and the next KPMG report in May may provide some insight. Still, the company is a long way from its targeted gearing level, implying substantial scope for further capital management. James Hardie is now operating at a higher pay-out ratio at 50-70% of underlying profit, ex asbestos, against 30-50% previously. Macquarie notes, even if operating at the top of this range, the company would need to pay out an increasing number of special dividends to push the balance sheet to the targeted gearing level. The broker is upbeat and has raised the rating to Outperform from Neutral.
A lot of commentary is on the growth in the US market but what about Australia? Credit Suisse notes the renovations market here is soft and this is constraining volume growth. Still, approvals for detached homes are increasing and James Hardie's business is expected to track this growth. New Zealand's market continues to improve, particularly in Auckland and with the Christchurch re-building. In the Philippines growth is steady in James Hardie's core markets. UBS notes the recovery in Australia is sluggish. Housing approvals are strong, particularly detached housing, but renovations and non-residential remain challenging. JP Morgan was expecting a decline in the Asia Pacific earnings in the third quarter, because of the weakening Australian dollar, but the division managed to generate earnings growth of 7.2% thanks to a fall in unit costs.
On the FNArena database the recommendations are evenly distributed. There are two Buy ratings, three Hold and two Sell. The consensus price target is $13.97, suggesting 2.9% downside to the last share price and this compares with $12.62 ahead of the quarterly result. Targets range from $11.07 (CIMB) to $16.08 (Deutsche Bank). The dividend yield on FY14 forecasts is 4.3% and 5.5% on FY15.
Find out why FNArena subscribers like the service so much: "Your Feedback (Thank You)" - Warning this story contains unashamedly positive feedback on the service provided.